By Ludwig Burger (Reuters) -French drugmaker Sanofi on Friday increased its guidance for full-year earnings, citing strong sales of anti-inflammatory treatment Dupixent and closely-watched new drug launches. The Paris-based drugmaker…
PARIS (Reuters) – Healthcare companies Sanofi and partner Regeneron presented on Tuesday more positive data for their Dupixent product. The companies said new data showed that Dupixent showed a significant…
(Reuters) -Sanofi won expanded U.S. approval for its best-selling Dupixent injection to treat an allergic inflammation of the esophagus, the Food and Drug Administration said on Friday. There are more…